Susquehanna International Group, LLP C4 Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$4.43 - $7.38 $324,719 - $540,954	-73,300 Reduced 28.1%	187,600 $1.07 Million
Q2 2024 Aug 15, 2024	SELL	$4.05 - $8.1 $428,085 - $856,170	-105,700 Reduced 28.83%	260,900 $1.21 Million
Q1 2024 May 07, 2024	SELL	$5.3 - $11.0 $128,790 - $267,300	-24,300 Reduced 6.22%	366,600 $3 Million
Q4 2023 Feb 14, 2024	BUY	$1.18 - $6.03 $461,262 - $2.36 Million	390,900 New	390,900 $2.21 Million
Q4 2022 Feb 14, 2023	BUY	$5.42 - $10.24 $34,688 - $65,536	6,400 Added 51.2%	18,900 $111,000
Q3 2022 Nov 14, 2022	SELL	$8.03 - $12.77 $121,252 - $192,827	-15,100 Reduced 54.71%	12,500 $110,000
Q2 2022 Aug 15, 2022	SELL	$5.06 - $26.46 $43,010 - $224,910	-8,500 Reduced 23.55%	27,600 $208,000
Q1 2022 May 16, 2022	BUY	$19.99 - $33.23 $377,810 - $628,046	18,900 Added 109.88%	36,100 $876,000
Q4 2021 Feb 14, 2022	SELL	$29.39 - $46.86 $2.33 Million - $3.72 Million	-79,300 Reduced 82.18%	17,200 $554,000
Q3 2021 Nov 15, 2021	BUY	$35.91 - $50.5 $2.43 Million - $3.41 Million	67,600 Added 233.91%	96,500 $4.31 Million
Q2 2021 Aug 11, 2021	BUY	$30.39 - $42.18 $878,271 - $1.22 Million	28,900 New	28,900 $1.09 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $179M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.